Corneat Vision , Ltd.
CorNeat Vision is an ophthalmic medical device company developing synthetic, tissue-integrating implants for corneal, glaucoma and ocular-surface surgery. The company designs and validates biomimetic implants and associated implantation tools, advances preclinical and first-in-human studies, pursues regulatory clearances for synthetic tissue substitutes, and deploys remote telementoring solutions to support clinical adoption.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Artificial cornea (synthetic keratoprosthesis)
A biomimetic, fully synthetic corneal implant engineered to integrate permanently with the eye wall and restore optical function without donor tissue.
Synthetic scleral reinforcement patch (non-degradable)
Thin, sterile, non-degradable synthetic tissue patch intended to reinforce the sclera and reconstruct the ocular surface as an alternative to tissue grafts.
Glaucoma drainage device for refractory cases
A drainage implant intended to extend minimally invasive glaucoma surgery options for severe or refractory patients, designed to be concealed beneath tissue and integrated with surrounding structures.
Artificial cornea (synthetic keratoprosthesis)
A biomimetic, fully synthetic corneal implant engineered to integrate permanently with the eye wall and restore optical function without donor tissue.
Synthetic scleral reinforcement patch (non-degradable)
Thin, sterile, non-degradable synthetic tissue patch intended to reinforce the sclera and reconstruct the ocular surface as an alternative to tissue grafts.
Glaucoma drainage device for refractory cases
A drainage implant intended to extend minimally invasive glaucoma surgery options for severe or refractory patients, designed to be concealed beneath tissue and integrated with surrounding structures.
Services
Real-time remote surgeon virtual presence service for live surgical training and initiation of clinical sites using HD video and telementoring workflows.
Real-time remote surgeon virtual presence service for live surgical training and initiation of clinical sites using HD video and telementoring workflows.
Expertise Areas
- Biomaterials and tissue integration
- Ophthalmic implant design and development
- Preclinical safety and biocompatibility testing
- First-in-human clinical trial execution
Key Technologies
- Tissue-integrating synthetic biomaterials (non-degradable polymer matrices)
- Synthetic keratoprosthesis (artificial cornea)
- Synthetic scleral reinforcement membranes
- Glaucoma drainage device design
News & Updates
First implantations of the synthetic cornea at clinical centers in Paris and Montpellier, with media coverage and surgeon-reported outcomes.
Regulatory clearance by the U.S. FDA (510(k)) for a non-degradable synthetic tissue substitute intended for ophthalmic surgery.
Report of a bilaterally blind patient regaining visual function immediately after implantation of a biomimetic synthetic cornea in Israel.
Announcement of U.S. market availability for a synthetic tissue patch for ocular surgery, following regulatory clearance and surgeon endorsements.
Public description of the company's core tissue-integrating material technology, emphasizing fibroblast migration and ECM-mimicking properties.
Announcement of completed preclinical phase for an artificial cornea and a synthetic, non-degradable scleral patch ahead of clinical translation.
First implantations of the synthetic cornea at clinical centers in Paris and Montpellier, with media coverage and surgeon-reported outcomes.
Regulatory clearance by the U.S. FDA (510(k)) for a non-degradable synthetic tissue substitute intended for ophthalmic surgery.
Report of a bilaterally blind patient regaining visual function immediately after implantation of a biomimetic synthetic cornea in Israel.
Announcement of U.S. market availability for a synthetic tissue patch for ocular surgery, following regulatory clearance and surgeon endorsements.
Public description of the company's core tissue-integrating material technology, emphasizing fibroblast migration and ECM-mimicking properties.
Announcement of completed preclinical phase for an artificial cornea and a synthetic, non-degradable scleral patch ahead of clinical translation.